NewAmsterdam Pharma Announces Positive Topline Data from
...NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia July 29, 2024 08 ......
https://www.globenewswire.com/news-release/2024/7/29/2920256/0/en/NewAmsterdam-Pharma-Announces-Positive-Topline-Data-from-Pivotal-Phase-3-BROOKLYN-Clinical-Trial-Evaluating-Obicetrapib-in-Patients-with-Heterozygous-Familial-Hypercholesterolemia.html
Phase III BROOKLYN Trial Evaluating Obicetrapib in Patients with ...
...The CETP inhibitor lowered low-density lipoprotein cholesterol by 36.3% at day 84 and 41.5% at day 365 compared to placebo. NewAmsterdam Pharma has shared positive results from its pivotal Phase III BROOKLYN clinical trial (NCT05425745) evaluating obicetrapib in patients with heterozygous familial ......
https://www.appliedclinicaltrialsonline.com/view/phase-iii-brooklyn-trial-obicetrapib-heterozygous-familial-hypercholesterolemia
NewAmsterdam Pharma Reports Positive Topline Data of Alzheimer Agent ...
...Key Takeaways Obicetrapib significantly reduced p-tau217 levels, a key Alzheimer's biomarker, in the phase 3 BROADWAY trial. The trial involved patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia. Obicetrapib demonstrated a 33% reduction in LDL-C levels and improved other cardiovascular markers....
https://www.neurologylive.com/view/newamsterdam-pharma-reports-positive-topline-data-obicetrapib-phase-3-broadway-trial-ad
Learn About Obicetrapib From NewAmsterdam Pharma
...Mechanism Of Action Obicetrapib is currently being studied as a potential treatment to lower LDL-C as an adjunct to maximally tolerated lipid-lowering therapies in patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) in three pivotal Phase 3 trials: BROADWAY, BROOKLYN, and PREVAIL. 3-5...
https://www.newamsterdampharma.com/obicetrapibta8995/
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM ... - BioSpace
...NewAmsterdam Pharma Company N.V. announced the dosing of the first patient and initiation of TANDEM, a pivotal Phase 3 clinical trial to evaluate obicetrapib and ezetimibe FDC in adult patients with Heterozygous Familial Hypercholesterolemia and/or Atherosclerotic Cardiovascular Disease or multiple risk factors for ASCVD, whose LDL-C is not ......
https://www.biospace.com/newamsterdam-pharma-doses-first-patient-in-phase-3-tandem-clinical-trial-evaluating-fixed-dose-combination-of-obicetrapib-and-ezetimibe-in-patients-with-hefh-and-or-ascvd
NewAmsterdam Pharma announces positive topline data from the Phase 3 ...
...For whom existing therapies are not sufficiently effective or well-tolerated, announced positive topline data from the Company?s Phase 3 BROOKLYN clinical trial (NCT05425745). BROOKLYN, the first of four studies in NewAmsterdam?s pivotal clinical development program, was designed to evaluate obicetrapib in adult patients with heterozygous familial hypercholesterolemia (?HeFH?), whose ......
https://www.pharmaceutical-era.com/press-releases/newamsterdam-pharma-announces-positive-topline-data-from-the-phase-3-brooklyn-trial-of-obicetrapib-in-heterozygous-familial-hypercholesterolemia-patients?highlight=WyJwaGFybWFjZXV0aWNhbCIsImJpb3BoYXJtYWNldXRpY2FscyIsInBoYXJtYWNldXRpY3MiLCJwaGFybWFjZXV0aWNhbC1lcmEiLCJwaGFybWFjZXV0aWNhbC1lcmEncyIsInBoYXJtYWNldXRpY2FscyIsImJpb3BoYXJtYWNldXRpY2FsIiwicGhhcm1hY2V1dGljYWwtZ3JhZGUiLCJyYWRpb3BoYXJtYWNldXRpY2FscyIsImJpb3BoYXJtYWNldXRpY2FsJ3MiXQ==
NewAmsterdam Pharma Doses First Patient in Phase 3 BROOKLYN Clinical ...
...NewAmsterdam Pharma, a clinical-stage company focused on the research and development of transformative oral therapies for metabolic diseases, today announced the initiation of BROOKLYN, a pivotal Phase 3 clinical trial of obicetrapib in adult patients with a history of heterozygous familial hypercholesterolemia (HeFH), whose LDL-C is not adequately controlled despite being on maximally ......
https://www.pharmaceutical-tech.com/pressreleases/newamsterdam-pharma-doses-first-patient-in-phase-3-brooklyn-clinical-trial
NewAmsterdam?s Obicetrapib Slashes HeFH LDL-C in First Phase 3 Trial ...
...Topline results are in from NewAmsterdam Pharma?s BROOKLYN study, showing that obicetrapib safely and effectively reduces LDL cholesterol in patients with heterozygous familial hypercholesterolemia who can?t be effectively treated by current cholesterol drugs....
https://cardiacwire.com/newamsterdams-obicetrapib-slashes-hefh-ldl-c-in-first-phase-3-trial/
NewAmsterdam Pharma Reports Positive Phase 3 BROOKLYN Trial Results for ...
...NewAmsterdam Pharma Company N.V., a clinical biopharmaceutical entity focused on developing non-statin oral medications for cardiovascular disease (CVD) patients with elevated low-density lipoprotein cholesterol (LDL-C), announced positive topline results from its Phase 3 BROOKLYN clinical trial. The study evaluated the drug obicetrapib in patients with heterozygous familial ......
https://synapse.patsnap.com/article/newamsterdam-pharma-reports-positive-phase-3-brooklyn-trial-results-for-obicetrapib-in-heterozygous-familial-hypercholesterolemia
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 ...
...NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific ......
https://www.nasdaq.com/press-release/newamsterdam-pharma-presents-additional-data-pivotal-phase-3-brooklyn-clinical-trial
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase ...
...NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia December 10, 2024 | 16 min read...
https://www.biospace.com/press-releases/newamsterdam-pharma-announces-positive-topline-data-from-pivotal-phase-3-broadway-clinical-trial-evaluating-obicetrapib-in-patients-with-atherosclerotic-cardiovascular-disease-and-or-heterozygous-familial-hypercholesterolemia
NewAmsterdam's Obicetrapib Achieves 41.5% LDL-C Reduction in Phase 3 Trial
...NewAmsterdam Pharma announced additional results from its Phase 3 BROOKLYN trial evaluating obicetrapib in patients with heterozygous familial hypercholesterolemia. The trial met its primary endpoint with LDL-C mean reduction of 36.3% at day 84 and 41.5% at day 365 versus placebo. Secondary endpoints showed significant improvements, including Lp (a) reduction of 45.9% at day 84 and 54.3% at ......
https://www.stocktitan.net/news/NAMS/new-amsterdam-pharma-presents-additional-data-from-pivotal-phase-3-vi6u9fqxa1a0.html